Success Metrics

Active Trials
0(0%)

Phase Distribution

Ph phase_2
3
100%

Phase Distribution

0

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
3(100.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Active(1)
Other(2)

Detailed Status

Suspended2
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
N/A
Most Advanced
Phase 2

Trials by Phase

Phase 23 (100.0%)

Trials by Status

not_yet_recruiting133%
suspended267%

Recent Activity

0 active trials
Showing 3 of 3
not_yet_recruitingphase_2

CANnabinoids for Drug Resistant Epilepsy (DRE) in Adults and Children

NCT07023744
suspendedphase_2

CBD Oil for Reducing Emotional Impact of COVID-19

NCT04603781
suspendedphase_2

Use of CBD Oil in the Treatment of Posttraumatic Stress Disorder

NCT04197102

Clinical Trials (3)

Showing 3 of 3 trials
NCT07023744Phase 2

CANnabinoids for Drug Resistant Epilepsy (DRE) in Adults and Children

Not Yet Recruiting
NCT04603781Phase 2

CBD Oil for Reducing Emotional Impact of COVID-19

Suspended
NCT04197102Phase 2

Use of CBD Oil in the Treatment of Posttraumatic Stress Disorder

Suspended

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3